“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi...
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...